Literature DB >> 34752752

A rare insight into the immunosuppressive landscape of prostate cancer bone metastases.

Claudia Palena1, James L Gulley2.   

Abstract

Therapeutic options for metastatic prostate cancer patients are currently limited. In this issue of Cancer Cell, Kfoury et al. characterized the tumor and immune compartments of prostate cancer bone metastasis, revealing a mechanism of immunosuppression that involves infiltration with M2 macrophages and T cell exhaustion mediated by the CCL20-CCR6 axis. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2021        PMID： 34752752      PMCID： PMC9563857          DOI： 10.1016/j.ccell.2021.09.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  10 in total

Review 1.  Macrophages: The Road Less Traveled, Changing Anticancer Therapy.

Authors:  Jennifer L Guerriero
Journal:  Trends Mol Med       Date:  2018-04-11       Impact factor: 11.951

2.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.

Authors:  Daniele V F Tauriello; Sergio Palomo-Ponce; Diana Stork; Antonio Berenguer-Llergo; Jordi Badia-Ramentol; Mar Iglesias; Marta Sevillano; Sales Ibiza; Adrià Cañellas; Xavier Hernando-Momblona; Daniel Byrom; Joan A Matarin; Alexandre Calon; Elisa I Rivas; Angel R Nebreda; Antoni Riera; Camille Stephan-Otto Attolini; Eduard Batlle
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

3.  Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.

Authors:  Youmna Kfoury; Ninib Baryawno; Nicolas Severe; Shenglin Mei; Karin Gustafsson; Taghreed Hirz; Thomas Brouse; Elizabeth W Scadden; Anna A Igolkina; Konstantinos Kokkaliaris; Bryan D Choi; Nikolas Barkas; Mark A Randolph; John H Shin; Philip J Saylor; David T Scadden; David B Sykes; Peter V Kharchenko
Journal:  Cancer Cell       Date:  2021-10-15       Impact factor: 31.743

Review 4.  Macrophages as regulators of tumour immunity and immunotherapy.

Authors:  David G DeNardo; Brian Ruffell
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

5.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

Review 6.  Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.

Authors:  Hanne Lind; Sofia R Gameiro; Caroline Jochems; Renee N Donahue; Julius Strauss; James L Gulley; Claudia Palena; Jeffrey Schlom
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

7.  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.

Authors:  Julius Strauss; Margaret E Gatti-Mays; Byoung Chul Cho; Andrew Hill; Sébastien Salas; Edward McClay; Jason M Redman; Houssein A Sater; Renee N Donahue; Caroline Jochems; Elizabeth Lamping; Andrea Burmeister; Jennifer L Marté; Lisa M Cordes; Marijo Bilusic; Fatima Karzai; Laureen S Ojalvo; Genevieve Jehl; P Alexander Rolfe; Christian S Hinrichs; Ravi A Madan; Jeffrey Schlom; James L Gulley
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

8.  Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.

Authors:  Jason M Redman; Seth M Steinberg; James L Gulley
Journal:  J Immunother Cancer       Date:  2018-09-18       Impact factor: 13.751

Review 9.  How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.

Authors:  Jacob Stultz; Lawrence Fong
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-04-05       Impact factor: 5.554

10.  Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.

Authors:  Farhad Islami; Elizabeth M Ward; Hyuna Sung; Kathleen A Cronin; Florence K L Tangka; Recinda L Sherman; Jingxuan Zhao; Robert N Anderson; S Jane Henley; K Robin Yabroff; Ahmedin Jemal; Vicki B Benard
Journal:  J Natl Cancer Inst       Date:  2021-07-08       Impact factor: 13.506
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.